1. Home
  2. VTS vs GERN Comparison

VTS vs GERN Comparison

Compare VTS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vitesse Energy Inc.

VTS

Vitesse Energy Inc.

HOLD

Current Price

$16.05

Market Cap

742.9M

Sector

Energy

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.36

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTS
GERN
Founded
2014
1990
Country
United States
United States
Employees
N/A
258
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
742.9M
808.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VTS
GERN
Price
$16.05
$1.36
Analyst Decision
Hold
Hold
Analyst Count
1
3
Target Price
$20.00
$2.17
AVG Volume (30 Days)
588.4K
12.5M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
11.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$273,989,000.00
N/A
Revenue This Year
$5.48
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
13.22
N/A
52 Week Low
$15.76
$1.04
52 Week High
$27.15
$2.01

Technical Indicators

Market Signals
Indicator
VTS
GERN
Relative Strength Index (RSI) 35.15 61.20
Support Level N/A $1.22
Resistance Level $20.13 $1.46
Average True Range (ATR) 0.49 0.07
MACD -0.13 0.03
Stochastic Oscillator 11.65 93.10

Price Performance

Historical Comparison
VTS
GERN

About VTS Vitesse Energy Inc.

Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: